RecruitingNot ApplicableNCT06195605

Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin


Sponsor

University of Michigan

Enrollment

15 participants

Start Date

May 9, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of the study is to investigate the impact of the injection of dermal filler on the quality of the skin dermal extracellular matrix in persons between the ages of 30-50 years. The quality of the dermal extracellular matrix will be assessed following injection of dermal filler compared to injection of saline vehicle.


Eligibility

Min Age: 30 YearsMax Age: 50 Years

Inclusion Criteria3

  • Subjects must understand and sign the informed consent prior to participation
  • Subjects must be in generally good health
  • Subjects must be able and willing to comply with the requirements of the protocol

Exclusion Criteria16

  • Pregnant, plan to become pregnant during the study, or are nursing a child. Participants will be asked to self-report pregnancy
  • Individuals with bleeding disorders
  • Tend to heal poorly or form very thick scars called keloids
  • Have a lidocaine sensitivity, including those with epilepsy, impaired cardiac conduction, severely impaired hepatic function or severe renal dysfunction.
  • Individuals with active inflammation or infection of the skin, including active herpes infection.
  • Have a significant medical history or concurrent condition which the investigator(s) feel is not safe for study participation, including history of frequent herpes infections, and subjects planning to be exposed to excessive sun, Ultraviolet lamps and extreme cold weather during the first week after injection.
  • History of allergies to gram positive bacterial proteins
  • Individuals with who have undergone therapy with thrombolytics, anticoagulants, or inhibitors of platelet aggregation in the preceding 3 weeks.
  • Have an active inflammation or infection of the skin near the site of injection
  • Are taking any medications that suppress your immune system
  • Have severe allergies to medications or other things that we believe might make participation unsafe for you
  • Have a history of connective tissue diseases, such as:
  • rheumatoid arthritis
  • scleroderma
  • polymyositis/dermatomyositis
  • systemic lupus erythematosus (SLE)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICERestylane-L

Using a small gauge metal hub needle, two injections of CL-HA dermal filler (Restylane-L) will be performed, each into a small area (approximately 2 x 2 cm) of the mid-dermis of a forearm of a subject. Each injection will be 0.5 cc in volume, and will be approximately 2 cm apart from each other

DEVICEVehicle

Two injections of vehicle will be performed in the same manner as Restylane-L and in the same forearm, totaling 4 injections. A plastic template will be used to track the location of the injections, relative to landmarks on the skin.


Locations(1)

University of Michigan

Ann Arbor, Michigan, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06195605


Related Trials